This is not likely how it's going to work. You don't give two separate immunotherapies essentially simultaneously. If HOT and NEO both work, then patients will be tried on the off-the-shelf, cheaper, and faster method first. If that fails, then perhaps NEO would be tried.
I still don't see why they must have HOT. The treatment cost of everything comes down, and the time to generate a NEO vaccine will almost certainly come down with time. HOT will always be available faster, but it's not guaranteed how much faster or whether it will be worth it from an effectiveness standpoint. Amgen may know a lot more about it than we do, and may not be interested.
News 
Market Data 
Discover 
AI
